Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EMA Emera Inc.

未开盘 07-15 16:00:00 EDT

45.50

-0.20

-0.44%

盘后45.50

+0.000.00%

16:39 EDT

最高45.81	最低45.35	成交量10.13万
今开45.81	昨收45.70	日振幅1.01%
总市值135.54亿	流通市值135.42亿	总股本2.98亿
成交额461.15万	换手率0.03%	流通股本2.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.5,"timestamp":1752609600000,"preClose":45.7,"halted":0,"volume":101254,"hourTrading":{"tag":"盘后","latestPrice":45.5,"preClose":45.5,"latestTime":"16:39 EDT","volume":47686,"amount":2173556.02918,"timestamp":1752611947815},"delay":0,"floatShares":297632664,"shares":297900000,"eps":2.069006,"marketStatus":"未开盘","change":-0.2,"latestTime":"07-15 16:00:00 EDT","open":45.81,"high":45.81,"low":45.35,"amount":4611533.641848,"amplitude":0.010066,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.069006,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752652800000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":45.7,"dividendRate":0.046303,"postHourTrading":{"tag":"盘后","latestPrice":45.5,"preClose":45.5,"latestTime":"16:39 EDT","volume":47686,"amount":2173556.02918,"timestamp":1752611947815},"volumeRatio":1.247603,"impliedVol":0,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"2550681411","title":"诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550681411?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月8日，诺和诺德(NVO.US)宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理，用于体重管理。此次上市申请是基于III期STEP UP研究和III期STEP UP T2D研究的积极结果。结果显示，患者平均基线体重为113kg，治疗第72周，7.2mg司美格鲁肽组、2.4mg司美格鲁肽组和安慰剂组患者的体重分别减轻了20.7%、17.5%和2.4%。此外，7.2mg司美格鲁肽组有33.2%的患者实现了体重减轻25%以上的效果，而2.4mg司美格鲁肽组和安慰剂组的这一比例分别为16.7%和0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4532","BK4081","BK4588","NVO","BK4599","BK4007","EMA","LU1093756168.USD","LU0154236417.USD","BK4585"],"gpt_icon":0},{"id":"2546642507","title":"突破通用领域推理的瓶颈！清华NLP实验室强化学习新研究RLPR","url":"https://stock-news.laohu8.com/highlight/detail?id=2546642507","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546642507?lang=zh_cn&edition=full","pubTime":"2025-06-27 10:30","pubTimestamp":1750991400,"startTime":"0","endTime":"0","summary":"针对这一关键挑战，清华大学自然语言处理实验室提出了一项关键性技术 —— 基于参考概率奖励的强化学习。同时，RLPR 提出基于奖励标准差的动态过滤机制，进一步提升强化学习的稳定性和性能提升。目前 RLPR 相关代码、模型、数据、论文均已开源。结果表明，PR 在 0.5B 规模即取得了显著优于规则奖励和验证器模型奖励的质量。RLPR 在 Gemma、Llama、Qwen 等不同基座模型上均稳定提升推理能力总结RLPR 提出了创新的 Prob-to-Reward 奖励机制，解决了现有 RLVR 范式的领域依赖问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-27/doc-infcnrzr2751855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","RL","BK4588","BK4081","LU0006061336.USD","BK4585","BK4202"],"gpt_icon":0},{"id":"2546275727","title":"乐普生物：EGFR ADC联合PD-1单抗IND申请获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546275727","media":"生物药大时代","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546275727?lang=zh_cn&edition=full","pubTime":"2025-06-26 09:45","pubTimestamp":1750902347,"startTime":"0","endTime":"0","summary":"2025年6月24日，乐普生物科技股份有限公司的MRG003联合普特利单抗对比MRG003单药治疗局部晚期头颈鳞癌的II期研究的临床试验申请获得欧洲药品管理局批准，计划将于2025Q3启动入组。该研究是全球首个EGFR ADC联合PD-1单抗在局晚期头颈鳞癌的临床研究。EGFR ADC与普特利单抗联合治疗在EGFR阳性实体瘤患者中具有良好的耐受性和令人鼓舞的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","BK1161","EMA"],"gpt_icon":0},{"id":"2545847686","title":"港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545847686?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海普瑞午前涨超3%，截至发稿，涨3.09%，报5.33港元，成交额872.01万港元。消息面上，海普瑞发布公告，公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍，海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三条预灌封生产线设计产能为3.3亿支╱年，其按照中国、欧美药品法规标准设计建造，用于生产依诺肝素钠预灌封注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK1191","002399","EMA","09989","BK4081","BK0070"],"gpt_icon":0},{"id":"2544194287","title":"一年两针！吉利德突破性长效HIV疗法获FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544194287","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544194287?lang=zh_cn&edition=full","pubTime":"2025-06-20 07:31","pubTimestamp":1750375894,"startTime":"0","endTime":"0","summary":"4吉利德深耕HIV领域吉利德科学公司在HIV治疗和预防领域拥有超过35年的创新经验。吉利德致力于通过科学创新提供满足HIV患者不断变化需求的解决方案。通过与全球健康倡导者和组织的合作，吉利德还旨在改善教育、扩大药物可及性，并解决护理障碍，目标是终结全球HIV流行。这种每年仅需注射两次的长效方案有望显著提高患者的依从性，降低HIV传播风险，推动全球HIV预防目标的实现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","LU1571399168.USD","LU1585245621.USD","MAA","LU2087621335.USD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0058720904.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1430594728.SGD","GILD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4532","LU0320765992.SGD","BK4568","BK4550","IE00BSNM7G36.USD","LU1066051498.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","BK4566","BK4583","LU1066053197.SGD","BK4139","BK4578","LU0823416689.USD","LU1778281490.HKD","BK4588","BK4585","LU2089984988.USD","LU0109394709.USD","LU1674673428.USD","IE0002270589.USD","LU2468319806.SGD","BK4081","BK4215"],"gpt_icon":0},{"id":"2544549439","title":"海普瑞(002399.SZ)：依诺肝素钠注射液获得EMA新增生产商批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2544549439","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544549439?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:51","pubTimestamp":1750150299,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(002399.SZ)发布公告，公司近日收到欧洲药品管理局(“EMA”)签发的关于依诺肝素钠注射液新增成品制造商的批准通知。本次公司坪山园区预灌封制剂生产线获得EMA的许可，标志着公司坪山园区生产的依诺肝素钠注射液已获得在欧洲经济区(EEA)实现商业化的资格，本次获批将为公司进一步推进制剂国际化战略提供更加充足的产能保障，切实提高公司市场竞争力;同时，依托强大的预灌针生产能力，以及公司成熟的自营销售网络及渠道，公司助力中国药企药品出海欧美市场的战略将得到有力的支持和推动，对公司未来业务拓展有深远且积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","002399","BK0070","EMA","BK4081","BK0188","09989"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0082},{"period":"3month","weight":0.0049},{"period":"ytd","weight":0.0049}],"compareEarnings":[{"period":"1week","weight":0.0029},{"period":"1month","weight":0.0421},{"period":"3month","weight":0.1835},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.0615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Incorporated是一家北美能源服务提供商，成立于1998年7月23日，拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州，另外还在加拿大大西洋省、新墨西哥州和加勒比地区开展业务。Emera总部位于新斯科舍省哈利法克斯。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}